Cytori Reports Sustained Benefits at 18 Months in Cardiac Cell Therapy Heart Attack Trial

SAN DIEGO, CA--(Marketwire - June 8, 2011) - Cytori Therapeutics (NASDAQ: CYTX)
is reporting 18 month outcomes from its APOLLO trialfor Acute Myocardial
Infarction (AMI). The results from the 14 patient, randomized, placebo-
controlled, double-blind safety and feasibility trial in patients with ST-
elevation AMI demonstrated the following:
  * Mean reduction in infarct size at 6 months was preserved at 18 months for
    the cell treated group (standard-of-care plus cells), at 11.7% and 11.2%,
    respectively. In contrast, patients receiving control (standard-of-care plus
    placebo), exhibited diminished treatment effect from 6 months (6.1%) to 18
    months (4.4%);
 
  * The mean reduction in left ventricular infarct size (reduction in the
    portion of the heart damaged by the heart attack) was statistically
    significant (p < 0.05) from baseline to 18 months in the cell-treated group.
    In patients receiving control, there was less improvement which was not
    statistically significant;
 
  * Statistically significant (p < 0.05) improvement in perfusion of the left
    ventricle (blood flow through the tissue of the heart) from baseline to 18
    months was observed in the cell-treated group. In patients receiving control
    treatment, there was less improvement which was not statistically
    significant; and
 
  * There were substantially fewer premature ventricular beats (PVBs) per holter
    recording in patients who had received cells compared to those who had
    received control (mean of 24 and 146 PVBs per recording, respectively).
 
"There is a strong correlation between infarct size and clinical outcomes," said
Henricus Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular
Cardiology, Thoraxcenter, Erasmus University Hospital. "The APOLLO data
demonstrate there was a persistent beneficial effect from the cells that we
believe if repeated in ADVANCE should translate into superior outcomes for
patients. This is very encouraging for the field of cardiac cell therapy given
that this is one of the first randomized and double-blind trials to demonstrate
sustained improvement in outcomes in heart attack patients as far out as 18
months."
 
"Heart disease has been the leading killer for more than 100 years and is one of
the greatest financial burdens on the healthcare system," said Christopher J.
Calhoun, chief executive officer for Cytori. "Reductions of this magnitude in
infarct size, if shown to be reproducible in a larger trial would beneficially
impact long-term outcomes for patients, including MACCE, the development of
chronic ischemia and death. While APOLLO was a safety and feasibility trial,
Cytori's larger European trial ADVANCE is designed to demonstrate efficacy,
economic impact and the long-term benefit in patient outcomes in up to 370
patients."
 
As part of this novel procedure, a small amount of fat tissue was removed from
each patient's abdomen via liposuction shortly after his or her heart attack.
Using a proprietary medical device, the Celution® System developed by Cytori,
stem and regenerative cells were rapidly separated from each patient's fat
tissue and concentrated at the point-of-care, in the catheter laboratory. The
cells were then immediately prepared and infused into the patient's coronary
artery. All patients were treated within one day after the successful
revascularization of the infarcted artery that caused the heart attack.
 
As previously reported, the procedure was found to be safe. There were no new
major adverse cardiac or coronary events (MACCE) reported between the six and
18 month follow-up. Two MACCE events were reported between baseline and the six
month follow up, neither of which was attributed to the procedure. Additionally,
at the time of injection, no effect on TIMI flow or coronary flow reserve was
noted during and after infusion of cells or placebo, suggesting little or no
micro-vascular obstruction by the infused cells.
 
These new long-term data will be presented on Friday, June 10 at the 8th
International Symposium on Stem Cell Therapy & Cardiovascular Innovation in
Madrid, Spain by Dr. Duckers, Co-Principal Investigator for the trial. All MRI
data were analyzed by an independent blinded core laboratory. The core
laboratory remained blinded to patients' treatment assignments through 18
months.
 
The APOLLO trial is led by co-Principal Investigators Patrick W. Serruys, M.D.,
Ph.D., Professor of Interventional Cardiology at the Thoraxcenter, Erasmus
University Hospital and Dr. Duckers. Francisco F. Avilés, M.D., Ph.D., Professor
of Medicine and Chief of Department of Cardiology at Hospital General
Universitario Gregorio Marañón in Madrid also participated in this trial.
 
Cytori is currently enrolling patients in the pivotal ADVANCE trial in Europe,
designed to treat the same ST-elevation acute heart attack patients as in the
APOLLO trial. ST-elevation heart attacks are a severe form of heart attack in
which blood supply is cut off from the heart for a prolonged period of time,
impacting a large portion of the heart muscle. Approximately 1.3 million
patients in the United States and 1.9 million in Europe suffer from acute heart
attacks each year.
 
Graph and video available:
http://www2.marketwire.com/mw/release_html_b1?release_id=764125
 
About Cytori
 
Cytori is a leader in providing patients and physicians around the world with
medical technologies that harness the potential of adult regenerative cells from
adipose tissue. The Celution® System family of medical devices and instruments
is being sold into the European and Asian cosmetic and reconstructive surgery
markets but is not yet available in the United States. Our StemSource® product
line is sold globally for cell banking and research applications. Our
PureGraft(TM) products are available in North America and Europe for fat
grafting procedures. www.cytori.com
 
Cautionary Statement Regarding Forward-Looking Statements
 
This press release includes forward-looking statements regarding events, trends,
business prospects and particularly the APOLLO clinical study results, which may
affect our future operating results and financial position. Such statements,
including, but not limited to, those regarding improvements in patient outcomes,
the significance of the physiological and functional effects from the pilot
APOLLO study, and the effectiveness of the design of the ADVANCE study, are all
subject to risks and uncertainties that could cause the results of the more
comprehensive ADVANCE study to differ materially from those presented above.
Some of these risks and uncertainties include, but are not limited to, risks
related to the statistical power of the APOLLO study, the inherent risk and
uncertainty in the costs and potential variability of outcomes of a pivotal
heart attack study, uncertainties regarding the collection and results of
clinical data, and dependence on third party performance, as well as other risks
and uncertainties described under the "Risk Factors" in Cytori's Securities and
Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no
responsibility to update or revise any forward-looking statements to reflect
events, trends or circumstances after the date they are made.
 
Contact
 
Investors
Tom Baker
tbaker@cytori.com
+1.858.875.5258
 
US Media:
Megan McCormick
mmccormick@cytori.com
+1.858.875.5279
 
European Media:
Gemma Howe
College Hill
Gemma.howe@collegehill.com
+44 20 7866 7860
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Cytori Therapeutics, Inc. via Thomson Reuters ONE
 
[HUG#1522025]